Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I-II Study of Tesetaxel Plus Capecitabine and Cisplatin in Subjects With Advanced Gastric Cancer.

Next Previous
Trial Profile

A Phase I-II Study of Tesetaxel Plus Capecitabine and Cisplatin in Subjects With Advanced Gastric Cancer.

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Tesetaxel (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 29 Jun 2011 This trial is expected to be a 'run-in' for a planned phase III trial of tesetaxel first-line therapy in advanced gastric cancer, according to a Genta media release.
  • 29 Jun 2011 Accrual at the first dosing level in phase I has been completed, according to a Genta media release.
  • 13 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top